City

Clinical trials near Dallas, United States

Active studies with a listed research site in Dallas, United States.

55active studies

22recruiting now

18countries represented

137largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 2

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Obesity, OverweightCondition

LY3305677, LY3841136Treatment

Argentina, United States56 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT06143956See eligibility →

Recruiting nowPhase 2

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Obesity, OverweightCondition

Macupatide, EloralintideTreatment

Argentina, Australia42 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07215559See eligibility →

Recruiting nowPhase 4

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

Psoriasis, Overweight or ObesityCondition

TirzepatideTreatment

United States39 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT06857942See eligibility →

Recruiting nowPhase 3

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

Obesity, OverweightCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Japan87 locations

AmgenSponsor

Updated 2026-09-03 · NCT07684235See eligibility →

Recruiting nowPhase 2

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

ABBV-295, PlaceboTreatment

Puerto Rico, United States38 locations

AbbVieSponsor

Updated 2026-09-03 · NCT07752979See eligibility →

Recruiting nowEarly Phase 1

Sympathetic Transduction in Obesity-associated Hypertension (OB-HTN)

Hypertension, ObesityCondition

Neuropeptide YTreatment

United States1 locations

University of Texas Southwestern Medical CenterSponsor

Updated 2026-09-03 · NCT04838678See eligibility →

Recruiting nowNot applicable

Effects of Obesity in the Aged

Obesity, AgingCondition

Mechanical unloading of the Thorax using an external cuirassTreatment

United States1 locations

University of Texas Southwestern Medical CenterSponsor

Updated 2026-09-02 · NCT05028309See eligibility →

Recruiting nowNot applicable

Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation

Drug Discontinuation, Substance Use DisordersCondition

Discontinuation and Reinitiation of TirzepatideTreatment

United States1 locations

The University of Texas at DallasSponsor

Updated 2026-09-02 · NCT07387796See eligibility →

Recruiting nowPhase 2

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

B-cell Acute Lymphoblastic Leukemia, ObesityCondition

IDEAL2 InterventionTreatment

United States16 locations

Etan OrgelSponsor

Updated 2026-08-19 · NCT05082519See eligibility →

Recruiting nowPhase 3

Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)

Alcohol Use DisorderCondition

Semaglutide, PlaceboTreatment

United States19 locations

VA Office of Research and DevelopmentSponsor

Updated 2026-08-12 · NCT07218354See eligibility →

Recruiting nowPhase 2

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

Overweight, ObesityCondition

Macupatide, EloralintideTreatment

United States40 locations

Eli Lilly and CompanySponsor

Updated 2026-08-06 · NCT07589608See eligibility →

Recruiting nowNot applicable

UTSW NORC Pilot Spinal Cord Injury Dietary Program

Obesity and Obesity-related Medical Conditions, Spinal Cord Injury, ChronicCondition

Telehealth with dieticianTreatment

United States1 locations

University of Texas Southwestern Medical CenterSponsor

Updated 2026-07-15 · NCT06924177See eligibility →

Recruiting nowPhase 2

Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy

Type 2 DiabetesCondition

icovamenib 100 mg, PlaceboTreatment

United States17 locations

Biomea Fusion Inc.Sponsor

Updated 2026-06-15 · NCT07502508See eligibility →

Recruiting nowNot applicable

Targeting Breathing Limitations to Improve Functional Outcomes in HFpEF

Heart Failure With Preserved Ejection Fraction, ObesityCondition

HeO2 gas mixture, Room air gas mixtureTreatment

United States1 locations

University of Texas Southwestern Medical CenterSponsor

Updated 2026-05-07 · NCT05723679See eligibility →

Recruiting nowNot applicable

Spinal Cord Injury Model Systems (SCIMS) - Education Module

Spinal Cord Injuries, ObesityCondition

PVA Consumer Guide, WebMDTreatment

United States3 locations

University of MiamiSponsor

Updated 2026-04-20 · NCT06003686See eligibility →

Recruiting nowNot applicable

Leg Heating in Pregnant Women With Obesity

High-risk PregnancyCondition

Leg heatingTreatment

United States1 locations

University of Texas Southwestern Medical CenterSponsor

Updated 2026-04-17 · NCT06932250See eligibility →

Recruiting nowNot applicable

Comparing Outcomes Among Children With Obesity in a Community Healthy Lifestyle Program

Pediatric Obesity, Pediatric OverweightCondition

Get Up & Go Healthy Lifestyle ProgramTreatment

United States1 locations

University of Texas Southwestern Medical CenterSponsor

Updated 2026-03-30 · NCT07342855See eligibility →

Recruiting nowNot applicable

IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion

Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS)Condition

Intervention 1: Adrenalectomy, Intervention 2: SemaglutideTreatment

United States1 locations

University of Texas Southwestern Medical CenterSponsor

Updated 2026-03-27 · NCT07361874See eligibility →

Recruiting nowNot applicable

Impact of Dietary Phosphate Excess on Exercise Capacity and Visceral Adiposity

Physical Inactivity, Phosphate OverloadCondition

Sodium Phosphate, Sodium ChlorideTreatment

United States1 locations

University of Texas Southwestern Medical CenterSponsor

Updated 2026-02-17 · NCT05147909See eligibility →

Recruiting nowPhase 2

Tirzepatide Weight Loss for MRD+ Early Breast Cancer

Breast Cancer, Breast NeoplasmsCondition

TirzepatideTreatment

United States1 locations

Baylor Research InstituteSponsor

Updated 2026-02-12 · NCT06517212See eligibility →

Recruiting nowPhase 2, Phase 3

Tailored Exercise Training Study Among Adults With HFpEF

HFpEF - Heart Failure With Preserved Ejection Fraction, Diabetic CardiomyopathiesCondition

Moderate-intensity continuous training (MCT), Resistance trainingTreatment

United States1 locations

University of Texas Southwestern Medical CenterSponsor

Updated 2025-10-31 · NCT07223242See eligibility →

Recruiting nowNot applicable

Healthy Living BEYOND Weight Study

Overweight or ObesityCondition

None - Observational studyTreatment

United States1 locations

American Heart AssociationSponsor

Updated 2025-08-06 · NCT07075341See eligibility →

Opening soonPhase 1

A Study of LY4329090 in Participants With Obesity or Overweight Who Are Otherwise Healthy

Obesity, OverweightCondition

LY4329090, PlaceboTreatment

Singapore, United States3 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07808073See eligibility →

Opening soonPhase 1

A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight

Obesity, OverweightCondition

Eloralintide, Combined oral contraceptiveTreatment

United States2 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07808060See eligibility →

Opening soonPhase 3

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

Overweight, ObesityCondition

Zenagamtide, SemaglutideTreatment

United States43 locations

Novo Nordisk A/SSponsor

Updated 2026-08-25 · NCT07668414See eligibility →

Opening soonPhase 3

AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

Overweight, ObesityCondition

zenagamtide, PlaceboTreatment

United States37 locations

Novo Nordisk A/SSponsor

Updated 2026-08-25 · NCT07720271See eligibility →

Opening soonNot applicable

Nutrition Intervention Optimization to Better Utilize Resources and Support Health

Diabete Type 2, Obesity & OverweightCondition

Meal kits, No-prep mealsTreatment

United States1 locations

Tufts UniversitySponsor

Updated 2026-07-20 · NCT07713836See eligibility →

Opening soonNot applicable

Scale-Up Evaluation Trial of the Diabetes Prevention Program to Improve Obesity and Cardiometabolic Health After Traumatic Brain Injury

Traumatic Brain Injury, Brain Injuries, TraumaticCondition

Group Lifestyle Balance for People with TBI (GLB-TBI)Treatment

United States1 locations

Baylor Research InstituteSponsor

Updated 2026-06-16 · NCT07648901See eligibility →

Invitation onlyNot applicable

Respiratory Effects of Obesity in Children: Longitudinal Consequences After 6 Years of Aging

Childhood ObesityCondition

Intervention not listedTreatment

United States1 locations

University of Texas Southwestern Medical CenterSponsor

Updated 2026-09-03 · NCT06447246See eligibility →

Invitation onlyNot applicable

The Effect of Adiposity on Muscle and Microvascular Function in HFpEF

Heart Failure With Preserved Ejection Fraction (HFPEF)Condition

Weight loss SOC Treatment with second generation anti-diabetic medicationsTreatment

United States1 locations

University of Texas Southwestern Medical CenterSponsor

Updated 2026-09-03 · NCT06930495See eligibility →

Invitation onlyPhase 2

An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder

Obesity, Methamphetamine Use DisorderCondition

TirzepatideTreatment

United States1 locations

University of Texas Southwestern Medical CenterSponsor

Updated 2026-08-21 · NCT07693608See eligibility →

Active, not recruitingPhase 2

A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation

ObesityCondition

Trevogrumab-Part A, Trevogrumab-Part B and Part CTreatment

Puerto Rico, United States60 locations

Regeneron PharmaceuticalsSponsor

Updated 2026-09-01 · NCT06299098See eligibility →

Active, not recruitingNot applicable

Influence of Obesity on Oxalate Metabolism and Handling in Calcium Oxalate Stone Formers

Kidney StoneCondition

Controlled Diet, Carbon-13 Oxalate and Sucralose IngestionTreatment

United States2 locations

University of Alabama at BirminghamSponsor

Updated 2026-08-26 · NCT04333745See eligibility →

Active, not recruitingPhase 2

Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)

Overweight, Type 2 DiabetesCondition

Petrelintide, PlaceboTreatment

United States48 locations

Zealand PharmaSponsor

Updated 2026-08-21 · NCT06926842See eligibility →

Active, not recruitingPhase 1, Phase 2

A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM

Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)Condition

ALN-4324, PlaceboTreatment

Argentina, Canada22 locations

Alnylam PharmaceuticalsSponsor

Updated 2026-08-14 · NCT06845202See eligibility →

Active, not recruitingPhase 3

A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term

ObesityCondition

CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)Treatment

United States46 locations

Novo Nordisk A/SSponsor

Updated 2026-07-24 · NCT07011667See eligibility →

Active, not recruitingPhase 3

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

Obesity, OverweightCondition

Retatrutide, PlaceboTreatment

Argentina, Canada40 locations

Eli Lilly and CompanySponsor

Updated 2026-07-23 · NCT07035093See eligibility →

Active, not recruitingPhase 1

Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity

Overweight, ObesityCondition

COC, Maridebart CafraglutideTreatment

United States2 locations

AmgenSponsor

Updated 2026-07-20 · NCT07523711See eligibility →

Active, not recruitingPhase 2

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Obesity, OverweightCondition

LY3841136, TirzepatideTreatment

Argentina, United States52 locations

Eli Lilly and CompanySponsor

Updated 2026-07-17 · NCT06603571See eligibility →

Active, not recruitingPhase 1

A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity

Obesity, OverweightCondition

Brenipatide, PlaceboTreatment

United States3 locations

Eli Lilly and CompanySponsor

Updated 2026-07-16 · NCT07476118See eligibility →

Active, not recruitingPhase 2

A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes

Type 2 Diabetes MellitusCondition

RO7795081, SemaglutideTreatment

Hungary, Poland50 locations

Hoffmann-La RocheSponsor

Updated 2026-07-07 · NCT07112872See eligibility →

Active, not recruitingPhase 2

MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial

Adult Obesity, Weight ManagementCondition

ECC4703, PlaceboTreatment

United States15 locations

EccogeneSponsor

Updated 2026-06-25 · NCT07505303See eligibility →

Active, not recruitingPhase 2

A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

Overweight or Obese, Type 2 Diabetes Mellitus (T2DM)Condition

Placebo, EnicepatideTreatment

Argentina, Canada70 locations

Carmot Therapeutics, Inc.Sponsor

Updated 2026-06-24 · NCT06628362See eligibility →

Active, not recruitingPhase 3

A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight

Obesity, OverweightCondition

RetatrutideTreatment

Argentina, Canada35 locations

Eli Lilly and CompanySponsor

Updated 2026-06-09 · NCT07357415See eligibility →

Active, not recruitingPhase 1

A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity

Obese But Otherwise Healthy ParticipantsCondition

CRB-913, PlaceboTreatment

United States15 locations

Corbus Pharmaceuticals Inc.Sponsor

Updated 2026-05-29 · NCT07310901See eligibility →

Active, not recruitingPhase 3

A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight

Obesity, OverweightCondition

Retatrutide, PlaceboTreatment

United Kingdom, United States31 locations

Eli Lilly and CompanySponsor

Updated 2026-04-17 · NCT07232719See eligibility →

Active, not recruitingPhase 2

Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus

Obese, ObesityCondition

HM15275, Placebo of HM15275Treatment

United States14 locations

Hanmi Pharmaceutical Company LimitedSponsor

Updated 2026-04-08 · NCT07205900See eligibility →

Active, not recruitingPhase 3

VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

Weight LossCondition

VK2735Treatment

Puerto Rico, United States127 locations

Viking Therapeutics, Inc.Sponsor

Updated 2026-04-07 · NCT07104383See eligibility →

Active, not recruitingPhase 1

Effect of Maridebart Cafraglutide on the Heart's Electrical Activity

Overweight, ObesityCondition

Maridebart Cafraglutide, MoxifloxacinTreatment

United States2 locations

AmgenSponsor

Updated 2026-01-23 · NCT07229157See eligibility →

Active, not recruitingPhase 3

A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity

ObesityCondition

Cagrilintide, SemaglutideTreatment

Belgium, Canada36 locations

Novo Nordisk A/SSponsor

Updated 2026-01-20 · NCT06780449See eligibility →

Active, not recruitingPhase 1

A Study of LY3537031 in Overweight, Obese, and Healthy Participants

Overweight, ObesityCondition

LY3537031, PlaceboTreatment

United States5 locations

Eli Lilly and CompanySponsor

Updated 2026-01-20 · NCT06606106See eligibility →

Active, not recruitingPhase 2

Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo

ObesityCondition

Nimacimab injection, Nimacimab placebo injectionTreatment

United States16 locations

Skye Bioscience, Inc.Sponsor

Updated 2026-01-14 · NCT06577090See eligibility →

Active, not recruitingPhase 4

DIALYSIS-TIR Study

Type 2 Diabetes, End Stage Renal Disease on DialysisCondition

Semaglutide, PlaceboTreatment

United States5 locations

University of Texas Southwestern Medical CenterSponsor

Updated 2026-01-13 · NCT06042153See eligibility →

Active, not recruitingPhase 3

VK2735 for Weight Management Phase 3

Weight LossCondition

VK2735Treatment

Puerto Rico, United States137 locations

Viking Therapeutics, Inc.Sponsor

Updated 2025-11-24 · NCT07104500See eligibility →

Active, not recruitingPhase 2

Tirzepatide for Obesity and Meth Use Disorder

Obesity, Methamphetamine Use DisorderCondition

TirzepatideTreatment

United States1 locations

University of Texas Southwestern Medical CenterSponsor

Updated 2025-06-12 · NCT06745128See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Dallas, United States

Current studies

Related cities